{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:50:06Z","timestamp":1793407806080,"version":"4.5.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100030692","name":"National Institute on Drug Abuse Intramural Research Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030692","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["biologicalpsychiatryjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.biopsych.2026.06.033","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:18:34Z","timestamp":1784675914000},"page":"823-830","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Glucagon-Like Peptide-1 Receptor Agonists as a Candidate Treatment for Opioid Use Disorder: From Rats to Humans"],"prefix":"10.1016","volume":"100","author":[{"given":"Patricia Sue","family":"Grigson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1233-8709","authenticated-orcid":false,"given":"Scott C.","family":"Bunce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R.","family":"Brick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1915-0274","authenticated-orcid":false,"given":"Christopher S.","family":"Freet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4549-3617","authenticated-orcid":false,"given":"Jennifer E.","family":"Nyland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7325-7729","authenticated-orcid":false,"given":"Sarah S.","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Brandl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7212-908X","authenticated-orcid":false,"given":"Elise","family":"Shealy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendall","family":"Huddleston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2026.06.033_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M15-0038","article-title":"Opioid prescribing after nonfatal overdose and association with repeated overdose: A cohort study","volume":"164","author":"Larochelle","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.biopsych.2026.06.033_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109604","article-title":"Buprenorphine\/naloxone and methadone effectiveness for reducing craving in individuals with prescription opioid use disorder: Exploratory results from an open-label, pragmatic randomized controlled trial","volume":"239","author":"McAnulty","year":"2022","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.biopsych.2026.06.033_bib3","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","article-title":"Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"393","author":"Haight","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2026.06.033_bib4","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways for opioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.biopsych.2026.06.033_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108447","article-title":"Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse","volume":"131","author":"Greiner","year":"2021","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.biopsych.2026.06.033_bib6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2026.06.033_bib7","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2014","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.biopsych.2026.06.033_bib9","article-title":"\u201cYou\u2019re not supposed to be on it forever\u201d: Medications to treat opioid use disorder (MOUD) related stigma among drug treatment providers and people who use opioids","volume":"16","author":"Dickson-Gomez","year":"2022","journal-title":"Subst Abuse"},{"key":"10.1016\/j.biopsych.2026.06.033_bib10","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12954-021-00535-y","article-title":"\u201cIt\u2019s like 'liquid handcuffs\u201d: The effects of take-home dosing policies on Methadone Maintenance Treatment (MMT) patients\u2019 lives","volume":"18","author":"Frank","year":"2021","journal-title":"Harm Reduct J"},{"key":"10.1016\/j.biopsych.2026.06.033_bib11","article-title":"Critical access medication for opioid use disorder (MOUD) treatment facilities in the continental United States","volume":"6","author":"Pollack","year":"2023","journal-title":"Drug Alcohol Depend Rep"},{"key":"10.1016\/j.biopsych.2026.06.033_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108093","article-title":"Geographic access to buprenorphine prescribers for patients who use public transit","volume":"117","author":"Drake","year":"2020","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.biopsych.2026.06.033_bib13","doi-asserted-by":"crossref","first-page":"1128.e1","DOI":"10.1016\/j.ajem.2018.03.052","article-title":"Severe opioid withdrawal precipitated by Vivitrol\u00ae","volume":"36","author":"Wightman","year":"2018","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.biopsych.2026.06.033_bib14","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1097\/ADM.0000000000000922","article-title":"Evidence of buprenorphine-precipitated withdrawal in persons who use fentanyl","volume":"16","author":"Varshneya","year":"2022","journal-title":"J Addict Med"},{"key":"10.1016\/j.biopsych.2026.06.033_bib15","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.35895","article-title":"Buprenorphine-precipitated withdrawal among hospitalized patients using fentanyl","volume":"7","author":"Thakrar","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.biopsych.2026.06.033_bib16","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.52136","article-title":"Barriers to buprenorphine initiation in patients using fentanyl","volume":"9","author":"Kawasaki","year":"2026","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.biopsych.2026.06.033_bib17","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/10826084.2023.2269571","article-title":"The perceived role of withdrawal in maintaining opioid addiction among adults with untreated opioid use disorder: A survey of syringe exchange program participants","volume":"59","author":"Hall","year":"2024","journal-title":"Subst Use Misuse"},{"key":"10.1016\/j.biopsych.2026.06.033_bib18","series-title":"CDC reports nearly 24% decline in U.S. Drug overdose deaths","year":"2025"},{"key":"10.1016\/j.biopsych.2026.06.033_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2023.102060","article-title":"Obesity, cardiovascular disease, and the promising role of semaglutide: Insights from the SELECT trial","volume":"49","author":"Irfan","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.biopsych.2026.06.033_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1395651","article-title":"The effectiveness of 0.5 mg and 1mg of semaglutide in patients with type two diabetes and predictors of response: A retrospective cohort study","volume":"15","author":"Alenzi","year":"2024","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.biopsych.2026.06.033_bib21","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41386-019-0531-4","article-title":"Activation of GLP-1 receptors attenuates oxycodone taking and seeking without compromising the antinociceptive effects of oxycodone in rats","volume":"45","author":"Zhang","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2026.06.033_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108599","article-title":"A novel dual agonist of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors attenuates fentanyl taking and seeking in male rats","volume":"192","author":"Zhang","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2026.06.033_bib23","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/j.neuropharm.2011.12.022","article-title":"The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide","volume":"62","author":"Kanoski","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2026.06.033_bib24","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/FBP.0000000000000609","article-title":"Glucagon-like peptide-1 receptor agonist, exendin-4, reduces reinstatement of heroin-seeking behavior in rats","volume":"32","author":"Douton","year":"2021","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.biopsych.2026.06.033_bib31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J Basic Clin Pharm"},{"key":"10.1016\/j.biopsych.2026.06.033_bib25","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/FBP.0000000000000685","article-title":"Acute glucagon-like peptide-1 receptor agonist liraglutide prevents cue-, stress-, and drug-induced heroin-seeking in rats","volume":"33","author":"Douton","year":"2022","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.biopsych.2026.06.033_bib26","doi-asserted-by":"crossref","DOI":"10.1111\/adb.13117","article-title":"Glucagon-like peptide-1 receptor agonist, liraglutide, reduces heroin self-administration and drug-induced reinstatement of heroin-seeking behaviour in rats","volume":"27","author":"Douton","year":"2022","journal-title":"Addict Biol"},{"key":"10.1016\/j.biopsych.2026.06.033_bib27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.brainresbull.2022.08.023","article-title":"Acute treatment with the glucagon-like peptide-1 receptor agonist, liraglutide, reduces cue- and drug-induced fentanyl seeking in rats","volume":"189","author":"Urbanik","year":"2022","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.biopsych.2026.06.033_bib28","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/FBP.0000000000000805","article-title":"Effect of acute treatment with the glucagon-like peptide-1 receptor agonist, liraglutide, and estrus phase on cue- and drug-induced fentanyl seeking in female rats","volume":"36","author":"Urbanik","year":"2025","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.biopsych.2026.06.033_bib29","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.brainresbull.2022.08.022","article-title":"Dose titration with the glucagon-like peptide-1 agonist, liraglutide, reduces cue- and drug-induced heroin seeking in high drug-taking rats","volume":"189","author":"Evans","year":"2022","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.biopsych.2026.06.033_bib30","doi-asserted-by":"crossref","DOI":"10.1097\/FBP.0000000000000880","article-title":"Acute glucagon-like peptide-1 receptor agonist, semaglutide, attenuates cue-, drug-, and stress-induced fentanyl seeking in male Sprague-Dawley rats","author":"Evans","year":"2026","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.biopsych.2026.06.033_bib32","author":"Whitfield"},{"key":"10.1016\/j.biopsych.2026.06.033_bib33","doi-asserted-by":"crossref","first-page":"E528","DOI":"10.1152\/ajpendo.00330.2023","article-title":"The antiemetic actions of GIP receptor agonism","volume":"326","author":"Borner","year":"2024","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.biopsych.2026.06.033_bib34","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.2337\/db21-0459","article-title":"GIP receptor agonism attenuates GLP-1 receptor agonist-induced nausea and emesis in preclinical models","volume":"70","author":"Borner","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.biopsych.2026.06.033_bib35","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1111\/bph.70096","article-title":"GLP-1R\/Y1 receptor\/Y2 receptor triple agonist decreases fentanyl-evoked dopamine release in the nucleus accumbens and attenuates fentanyl taking and seeking in rats","volume":"182","author":"Caffrey","year":"2025","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.biopsych.2026.06.033_bib36","doi-asserted-by":"crossref","DOI":"10.1523\/JNEUROSCI.2063-23.2024","article-title":"Populations of hindbrain glucagon-like peptide 1 (GLP1) neurons that innervate the hypothalamic PVH, thalamic PVT, or limbic forebrain BST have axon collaterals that reach all central regions innervated by GLP1 neurons","volume":"44","author":"Randolph","year":"2024","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2026.06.033_bib37","doi-asserted-by":"crossref","first-page":"16417","DOI":"10.1523\/JNEUROSCI.3267-14.2014","article-title":"Endogenous glucagon-like peptide-1 reduces drinking behavior and is differentially engaged by water and food intakes in rats","volume":"34","author":"McKay","year":"2014","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2026.06.033_bib38","article-title":"An endogenous GLP-1 circuit engages VTA GABA neurons to regulate mesolimbic dopamine neurons and attenuate cocaine seeking","author":"Merkel","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.biopsych.2026.06.033_bib39","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0443-18.2019","article-title":"Glucagon-like peptide-1 receptor agonist treatment does not reduce abuse-related effects of opioid drugs","volume":"6","author":"Bornebusch","year":"2019","journal-title":"eNeuro"},{"key":"10.1016\/j.biopsych.2026.06.033_bib40","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/adb.12295","article-title":"The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents","volume":"21","author":"Vall\u00f6f","year":"2016","journal-title":"Addict Biol"},{"key":"10.1016\/j.biopsych.2026.06.033_bib41","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.pbb.2017.07.014","article-title":"The glucagon-like peptide 1 receptor agonist Exendin-4 decreases relapse-like drinking in socially housed mice","volume":"160","author":"Thomsen","year":"2017","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.biopsych.2026.06.033_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104642","article-title":"Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats","volume":"93","author":"Aran\u00e4s","year":"2023","journal-title":"EBiomedicine"},{"key":"10.1016\/j.biopsych.2026.06.033_bib43","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41398-020-00923-1","article-title":"Long-term treatment with a glucagon-like peptide-1 receptor agonist reduces ethanol intake in male and female rats","volume":"10","author":"Vall\u00f6f","year":"2020","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.biopsych.2026.06.033_bib63","author":"Bunce"},{"key":"10.1016\/j.biopsych.2026.06.033_bib44","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13722-024-00481-7","article-title":"Ecological momentary assessment and cue-elicited drug craving as primary endpoints: Study protocol for a randomized, double-blind, placebo-controlled clinical trial testing the efficacy of a GLP-1 receptor agonist in opioid use disorder","volume":"19","author":"Freet","year":"2024","journal-title":"Addict Sci Clin Pract"},{"key":"10.1016\/j.biopsych.2026.06.033_bib45","author":"Freet"},{"key":"10.1016\/j.biopsych.2026.06.033_bib64","author":"Nyland"},{"key":"10.1016\/j.biopsych.2026.06.033_bib66","author":"Suzuki"},{"key":"10.1016\/j.biopsych.2026.06.033_bib65","author":"Winhusen"},{"key":"10.1016\/j.biopsych.2026.06.033_bib46","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/add.16679","article-title":"The association between glucose-dependent insulinotropic polypeptide and\/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis","volume":"120","author":"Qeadan","year":"2025","journal-title":"Addiction"},{"key":"10.1016\/j.biopsych.2026.06.033_bib47","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.35247","article-title":"Semaglutide and opioid overdose risk in patients with type 2 diabetes and opioid use disorder","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.biopsych.2026.06.033_bib48","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/oby.70024","article-title":"GLP-1 receptor agonists and substance use disorders in older adults with type 2 diabetes: A target trial emulation","author":"Dai","year":"2026","journal-title":"Obesity (Silver Spring) 34 Suppl 2"},{"key":"10.1016\/j.biopsych.2026.06.033_bib49","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","article-title":"Mapping the effectiveness and risks of GLP-1 receptor agonists","volume":"31","author":"Xie","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.biopsych.2026.06.033_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102726","article-title":"12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: A propensity-score matched cohort study","volume":"74","author":"De Giorgi","year":"2024","journal-title":"EClinicalmedicine"},{"key":"10.1016\/j.biopsych.2026.06.033_bib51","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/s41598-022-05323-7","article-title":"Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis","volume":"12","author":"Meurot","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.biopsych.2026.06.033_bib52","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1056\/NEJMoa2403664","article-title":"Once-weekly semaglutide in persons with obesity and knee osteoarthritis","volume":"391","author":"Bliddal","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biopsych.2026.06.033_bib53","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/ajcn\/nqaa328","article-title":"Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: A randomized controlled trial","volume":"113","author":"Gudbergsen","year":"2021","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.biopsych.2026.06.033_bib54","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.13738","article-title":"The glucagon-like peptide-1 receptor agonist, exendin-4, ameliorated gastrointestinal dysfunction in the Wistar Kyoto rat model of irritable bowel syndrome","volume":"32","author":"O\u2019Brien","year":"2020","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.biopsych.2026.06.033_bib55","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/jgh.13808","article-title":"Glucagon-like peptide-1 analog, liraglutide, improves visceral sensation and gut permeability in rats","volume":"33","author":"Nozu","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.biopsych.2026.06.033_bib56","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1080\/00365521.2022.2041084","article-title":"Pain relief and pain intensity response to GLP-1 receptor agonist ROSE-010 in irritable bowel syndrome; clinical study cross-analysis with respect to patient characteristics","volume":"57","author":"Touny","year":"2022","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.biopsych.2026.06.033_bib57","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.bbrc.2020.05.080","article-title":"The GLP-1 receptor herbal agonist morroniside attenuates neuropathic pain via spinal microglial expression of IL-10 and beta-endorphin","volume":"530","author":"Tang","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.biopsych.2026.06.033_bib58","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10735-025-10440-4","article-title":"The effects of the GLP1 analog liraglutide on allodynia and motor coordination in peripheral neuropathy induced by a chemotherapeutic agent, cisplatin","volume":"56","author":"Ozatik","year":"2025","journal-title":"J Mol Histol"},{"key":"10.1016\/j.biopsych.2026.06.033_bib59","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1111\/jdi.13544","article-title":"Painful diabetic neuropathy is associated with increased nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control","volume":"12","author":"Ponirakis","year":"2021","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.biopsych.2026.06.033_bib60","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00125-023-06072-6","article-title":"Glucagon-like peptide-1 receptor agonists reverse nerve morphological abnormalities in diabetic peripheral neuropathy","volume":"67","author":"Dhanapalaratnam","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopsych.2026.06.033_bib61","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","article-title":"Once-weekly semaglutide in adults with alcohol use disorder: A randomized clinical trial","volume":"82","author":"Hendershot","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2026.06.033_bib62","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41586-026-10330-z","article-title":"Genetic predictors of GLP1 receptor agonist weight loss and side effects","volume":"653","author":"Su","year":"2026","journal-title":"Nature"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322326014034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322326014034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T09:43:40Z","timestamp":1789551820000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322326014034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":65,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0006322326014034"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2026.06.033","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-Like Peptide-1 Receptor Agonists as a Candidate Treatment for Opioid Use Disorder: From Rats to Humans","name":"articletitle","label":"Article Title"},{"value":"Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopsych.2026.06.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Society of Biological Psychiatry.","name":"copyright","label":"Copyright"}]}}